Multimodal imaging of tumor response to sorafenib combined with radiation therapy: Comparison between diffusion-weighted MRI, choline spectroscopy and 18F-FLT PET imaging

Contrast Media and Molecular Imaging

Volumn 8, Issue 3, 2013, Pages 274-280

  Karroum, Oussama ^a,b   Mignion, Lionel ^a,b   Kengen, Julie ^a,b   Karmani, Linda ^a,b   Levêque, Philippe ^a,b   Danhier, Pierre ^a,b   Magat, Julie ^a,b   Bol, Anne ^c   Labar, Daniel ^c   Grégoire, Vincent ^c   Bouzin, Caroline ^a   Feron, Olivier ^a   Gallez, Bernard ^a,b   Jordan, Bénédicte F ^a,b  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b not available   (Belgium)

^c Pole of Molecular Imaging Radiotherapy and Oncology   (Belgium)

Author keywords

Choline spectroscopy; DW MRI; Radiotherapy; Sorafenib

Indexed keywords

3' FLUOROTHYMIDINE F 18; CHOLINE; SORAFENIB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER RADIOTHERAPY; CELL DEATH; CELL PROLIFERATION; CONTROLLED STUDY; DIFFUSION COEFFICIENT; DIFFUSION WEIGHTED IMAGING; FIBROSARCOMA; MONOTHERAPY; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CHEMORADIOTHERAPY; CHOLINE; DIDEOXYNUCLEOSIDES; DIFFUSION MAGNETIC RESONANCE IMAGING; FIBROSARCOMA; MAGNETIC RESONANCE SPECTROSCOPY; MICE; NIACINAMIDE; PHENYLUREA COMPOUNDS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RADIOTHERAPY, CONFORMAL; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SUBTRACTION TECHNIQUE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84876784248     PISSN: 15554309     EISSN: 15554317     Source Type: Journal    
DOI: 10.1002/cmmi.1525     Document Type: Article

References (37)

1. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
2. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45(2):228-247.
3. Padhani AR, Liu G, Koh DM, Chenevert TL, Thoeny HC, Takahara T, Dzik-Jurasz A, Ross BD, Van Cauteren M, Collins D, Hammoud DA, Rustin GJ, Taouli B, Choyke PL. Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia 2009;11:102-125.
4. Brindle KM. Detection of apoptosis in tumors using magnetic resonance imaging and spectroscopy. Adv Enzyme Regul 2002;42:101-112.
5. Tunariu N, Kaye SB, Desouza NM. Functional imaging: what evidence is there for its utility in clinical trials of targeted therapies? Br J Cancer 2012; doi: 10.1038/bjc.2011.579
6. Jordan BF, Runquist M, Raghunand N, Baker A, Williams R, Kirkpatrick L, Powis G, Gillies RJ. Dynamic contrast-enhanced and diffusion MRI show rapid and dramatic changes in tumor microenvironment in response to inhibition of HIF-1alpha using PX-478. Neoplasia 2005;7:475-485.
7. Chen JH, Mehta RS, Baek HM, Nie K, Liu H, Lin MQ, Yu HJ, Nalcioglu O, Su MY. Clinical characteristics and biomarkers of breast cancer associated with choline concentration measured by (1) H MRS. NMR Biomed 2011;24:316-324.
8. Glunde K, Bhujwalla ZM, Ronen SM. Choline metabolism in malignant transformation. Nat Rev Cancer 2011;11:835-848.
9. Radermacher KA, Magat J, Bouzin C, Laurent S, Dresselaers T, Himmelreich U, Boutry S, Mahieu I, Vander Elst L, Feron O, Muller RN, Jordan BF, Gallez B. Multimodal assessment of early tumor response to chemotherapy: comparison between diffusion-weighted MRI, 1H-MR spectroscopy of choline and USPIO particles targeted at cell death. NMR Biomed 2012;25:514-522.
10. Barwick T, Bencherif B, Mountz JM, Avril N. Molecular PET and PET/CT imaging of tumour cell proliferation using F-18 fluoro- l-thymidine: a comprehensive evaluation. Nucl Med Commun 2009;30:908-917.
11. Soloviev D, Lewis D, Honess D, Aboagye E. [(18)F]FLT: an imaging biomarker of tumour proliferation for assessment of tumour response to treatment. Eur J Cancer 2012;48(4):416-424.
12. Shields AF, Grierson JR, Kozawa SM, Zheng M. Development of labeled thymidine analogs for imaging tumor proliferation. Nucl Med Biol 1996;23:17-22.
13. Gallagher FA, Kettunen MI, Hu DE, Jensen PR, Zandt RI, Karlsson M, Gisselsson A, Nelson SK, Witney TH, Bohndiek SE, Hansson G, Peitersen T, Lerche MH, Brindle KM. Production of hyperpolarized [1, 4-13C2]malate from [1, 4-13C2]fumarate is a marker of cell necrosis and treatment response in tumors. Proc Natl Acad Sci USA 2009;106(47):19801-19806.
14. 18F]-labeled isatin sulfonamide. Proc Natl Acad Sci USA 2009;106:16375-16380.
15. Karroum O, Kengen J, Danhier P, Magat J, Mignion L, Bouzin C, Verrax J, Charrette N, Starkel P, Calderon PB, Sonveaux P, Feron O, Grégoire V, Gallez B, Jordan BF. Tumor reoxygenation following administration of mitogen-activated protein kinase inhibitors: a rationale for combination with radiation therapy. Radiother Oncol 2012;105:64-71.
16. Pratilas CA, Solit DB. Targeting the mitogen-activated protein kinase pathway: physiological feedback and drug response. Clin Cancer Res 2010;16:3329-3334.
17. Eichler AF, Batchelor TT, Henson JW. Diffusion and perfusion imaging in subacute neurotoxicity following high-dose intravenous methotrexate. Neuro Oncol 2007;9:373-377.
18. Schraml C, Schwenzer NF, Martirosian P, Bitzer M, Lauer U, Claussen CD, Horger M. Diffusion-weighted MRI of advanced hepatocellular carcinoma during sorafenib treatment: initial results. AJR Am J Roentgenol 2009;193:W301-307.
19. Jordan BF, Black K, Robey IF, Runquist M, Powis G, Gillies RJ. Metabolite changes in HT-29 xenograft tumors following HIF-1alpha inhibition with PX-478 as studied by MR spectroscopy in vivo and ex vivo. NMR Biomed 2005;18:430-439.
20. Bonekamp S, Shen J, Salibi N, Lai HC, Geschwind J, Kamel IR. Early response of hepatic malignancies to locoregional therapy-value of diffusion-weighted magnetic resonance imaging and proton magnetic resonance spectroscopy. J Comput Assist Tomogr 2011;35:167-173.
21. Chen CY, Li CW, Kuo YT, Jaw TS, Wu DK, Jao JC, Hsu JS, Liu GC. Early response of hepatocellular carcinoma to transcatheter arterial chemoembolization: choline levels and MR diffusion constants - initial experience. Radiology 2006;239(2):448-456.
22. Pucar D, Koutcher JA, Shah A, Dyke JP, Schwartz L, Thaler H, Kurhanewicz J, Scardino PT, Kelly WK, Hricak H, Zakian KL. Preliminary assessment of magnetic resonance spectroscopic imaging in predicting treatment outcome in patients with prostate cancer at high risk for relapse. Clin Prostate Cancer 2004;3:174-181.
23. Beloueche-Babari M, Jackson LE, Al-Saffar NM, Workman P, Leach MO, Ronen SM. Magnetic resonance spectroscopy monitoring of mitogen-activated protein kinase signaling inhibition. Cancer Res 2005;65:3356-3363.
24. Liu D, Hutchinson OC, Osman S, Price P, Workman P, Aboagye EO. Use of radiolabelled choline as a pharmacodynamic marker for the signal transduction inhibitor geldanamycin. Br J Cancer 2002;87:783-789.
25. Jimenez B, Del Peso L, Montaner S, Esteve P, Lacal JC. Generation of phosphorylcholine as an essential event in the activation of Raf-1 and MAP-kinases in growth factors-induced mitogenic stimulation. J Cell Biochem 1995;57:141-149.
26. Glunde K, Shah T, Winnard PT Jr, Raman V, Takagi T, Vesuna F, Artemov D, Bhujwalla ZM. Hypoxia regulates choline kinase expression through hypoxia-inducible factor-1 α signaling in a human prostate cancer model. Cancer Res 2008;68:172-180.
27. 18F-FDG-PET). J Clin Oncol 2008;26:15600.
28. 18F]Fluorothymidine positron emission tomography before and 7days after gefitinib treatment predicts response in patients with advanced adenocarcinoma of the lung. Clin Cancer Res 2008;14:7423-7429.
29. 18F]fluorothymidine positron emission tomography is a sensitive method for imaging the response of BRAF-dependent tumors to MEK inhibition. Cancer Res 2007;67:11463-11469.
30. Leyton J, Smith G, Lees M, Perumal M, Nguyen QD, Aigbirhio FI, Golovko O, He Q, Workman P, Aboagye EO. Noninvasive imaging of cell proliferation following mitogenic extracellular kinase inhibition by PD0325901. Mol Cancer Ther 2008;7:3112-3121.
31. Peng CL, Guo W, Ji T, Ren T, Yang Y, Li DS, Qu HY, Li X, Tang S, Yan TQ, Tang XD. Sorafenib induces growth inhibition and apoptosis in human synovial sarcoma cells via inhibiting the RAF/MEK/ERK signaling pathway. Cancer Biol Ther 2009;8:1729-1736.
32. Huether A, Höpfner M, Baradari V, Schuppan D, Scherübl H. Sorafenib alone or as combination therapy for growth control of cholangiocarcinoma. Biochem Pharmacol 2007;73(9):1308-1317.
33. Plastaras JP, Kim SH, Liu YY, Dicker DT, Dorsey JF, McDonough J, Cerniglia G, Rajendran RR, Gupta A, Rustgi AK, Diehl JA, Smith CD, Flaherty KT, El-Deiry WS. Cell cycle dependent and schedule-dependent antitumor effects of sorafenib combined with radiation. Cancer Res 2007;67:9443-9454.
34. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307:58-62.
35. Volpe JP, Hunter N, Basic I, Milas L. Metastatic properties of murine sarcomas and carcinomas. I. Positive correlation with lung colonization and lack of correlation with s.c. tumor take. Clin Exp Metastasis 1985;3:281-294.
36. 18F] fluorothymidine using (5'-O-dimethoxytrityl-2'-deoxy-3'-O-nosyl-beta- d-threo pentofuranosyl) thymine and its 3-N-BOC-protected analogue as a labeling precursor. Nucl Med Biol 2003;30:151-157.
37. Huisman MC, Reder S, Weber AW, Ziegler SI, Schwaiger M. Performance evaluation of the Philips MOSAIC small animal PET scanner. Eur J Nucl Med Mol Imag 2007;34:532-540.